As more pet cats live primarily indoors, the prevalence of inactivity is increasing, resulting in rapidly increasing rates of obese/overweight felines currently at 59% (56 million clinically obese cats live in the United States alone). Left untreated, obesity in cats increases the risk of diabetes, heart disease, kidney disease, and arthritis/joint pain. Diet alteration alone is typically not sufficient treatment, and indoor cats have few options for exercise.
Along with the obesity trend, feline diabetes is on the rise. However, unlike humans, the only approved treatments available to cats are diet adjustment and insulin shots. 20% to 48% of diabetic cats are euthanized within a year, often because of sub-optimal treatment options. As cats (and pets in general) become more socially integrated into human households, there is increased demand and willingness to pay for feline health care. Concerned pet owners and veterinarians often resort to using expensive, difficult to administer, and untested human medications.
People are spending more on pet treatments than ever ($70 billion in 2017, with a 6.2% CAGR), yet many human treatments have not been translated to pets, despite having similar diseases.
Finding, subduing, and dosing pet cats frequently is difficult for the owner and stressful for the pet.
Felines left untreated often develop diabetes, joint disease and/or arthritis, heart disease, and/or kidney disease.
NanoPortal insertion can be performed in a quick, outpatient procedure.
NanoPortal is being designed to last for durations of at least 6 months.
Implantation ensures continuous dosing for the duration of the treatment.